Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
$4.49
-2.1%
$4.17
$3.09
$6.18
$578.81M1.171.05 million shs293,263 shs
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$13.17
+4.0%
$13.23
$9.40
$19.11
$1.11B1.731.23 million shs685,917 shs
908 Devices Inc. stock logo
MASS
908 Devices
$7.28
+3.5%
$8.13
$5.03
$9.34
$275.11M0.63295,750 shs82,540 shs
Transcat, Inc. stock logo
TRNS
Transcat
$88.16
+2.4%
$86.07
$50.23
$95.22
$823.51M0.69152,590 shs26,691 shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
-0.87%+1.55%+21.49%-1.08%+46.33%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-4.81%-11.34%-6.77%-10.28%+21.50%
908 Devices Inc. stock logo
MASS
908 Devices
-4.35%-11.57%-20.48%-3.17%+4.93%
Transcat, Inc. stock logo
TRNS
Transcat
-2.06%-6.75%-7.31%+5.48%+5.90%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
$4.49
-2.1%
$4.17
$3.09
$6.18
$578.81M1.171.05 million shs293,263 shs
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$13.17
+4.0%
$13.23
$9.40
$19.11
$1.11B1.731.23 million shs685,917 shs
908 Devices Inc. stock logo
MASS
908 Devices
$7.28
+3.5%
$8.13
$5.03
$9.34
$275.11M0.63295,750 shs82,540 shs
Transcat, Inc. stock logo
TRNS
Transcat
$88.16
+2.4%
$86.07
$50.23
$95.22
$823.51M0.69152,590 shs26,691 shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
-0.87%+1.55%+21.49%-1.08%+46.33%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-4.81%-11.34%-6.77%-10.28%+21.50%
908 Devices Inc. stock logo
MASS
908 Devices
-4.35%-11.57%-20.48%-3.17%+4.93%
Transcat, Inc. stock logo
TRNS
Transcat
-2.06%-6.75%-7.31%+5.48%+5.90%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
2.33
Hold$5.6924.18% Upside
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
2.89
Moderate Buy$43.75245.58% Upside
908 Devices Inc. stock logo
MASS
908 Devices
2.00
Hold$12.0070.70% Upside
Transcat, Inc. stock logo
TRNS
Transcat
2.50
Moderate Buy$105.5022.55% Upside

Current Analyst Ratings Breakdown

Latest MASS, EYPT, TRNS, and CTKB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Reiterated RatingSell (D-)
7/16/2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Initiated CoverageBuy$40.00
7/8/2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Initiated CoverageOverweight$47.00
7/1/2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Boost Price TargetBuy$29.00 ➝ $65.00
6/24/2026
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
Reiterated RatingSell (D-)
6/24/2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Reiterated RatingBuy$68.00
5/28/2026
Transcat, Inc. stock logo
TRNS
Transcat
UpgradeSell (D)Sell (D+)
5/15/2026
Transcat, Inc. stock logo
TRNS
Transcat
UpgradeStrong SellHold
5/13/2026
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
Lower Price TargetOverweight$5.50 ➝ $4.75
5/12/2026
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
Lower Price TargetEqual Weight$6.00 ➝ $5.50
5/11/2026
908 Devices Inc. stock logo
MASS
908 Devices
DowngradeHold (C-)Sell (D-)
(Data available from 7/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
$201.49M2.94N/AN/A$2.67 per share1.72
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$31.37M33.84N/AN/A$3.70 per share3.42
908 Devices Inc. stock logo
MASS
908 Devices
$56.20M4.73N/AN/A$3.97 per share1.77
Transcat, Inc. stock logo
TRNS
Transcat
$331.88M2.42$4.57 per share18.83$32.21 per share2.67
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
-$66.54M-$0.57N/A229.00N/A-36.25%-10.07%-7.56%8/5/2026 (Estimated)
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$231.96M-$3.50N/AN/AN/A-3,566.63%-110.54%-90.15%8/5/2026 (Estimated)
908 Devices Inc. stock logo
MASS
908 Devices
$19.49M-$1.00N/AN/AN/A-62.40%-14.03%-10.40%8/4/2026 (Estimated)
Transcat, Inc. stock logo
TRNS
Transcat
$5.38M$0.58148.4341.00N/A1.62%5.84%3.78%8/4/2026 (Estimated)

Latest MASS, EYPT, TRNS, and CTKB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2026Q2 2026
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
-$0.02N/AN/AN/A$47.31 millionN/A
8/5/2026Q2 2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$0.92N/AN/AN/A$0.39 millionN/A
8/4/2026Q2 2026
908 Devices Inc. stock logo
MASS
908 Devices
-$0.14N/AN/AN/A$15.42 millionN/A
8/4/2026Q1 2027
Transcat, Inc. stock logo
TRNS
Transcat
$0.37N/AN/AN/A$86.42 millionN/A
5/26/2026Q4 2026
Transcat, Inc. stock logo
TRNS
Transcat
$0.51$0.56+$0.05$0.21$89.79 million$89.33 million
5/7/2026Q1 2026
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
-$0.08-$0.15-$0.07-$0.15$44.23 million$44.14 million
5/6/2026Q1 2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$0.79-$0.99-$0.20-$0.99$0.35 million$0.70 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
N/AN/AN/AN/AN/A
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
N/AN/AN/AN/AN/A
908 Devices Inc. stock logo
MASS
908 Devices
N/AN/AN/AN/AN/A
Transcat, Inc. stock logo
TRNS
Transcat
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
N/A
4.69
4.07
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
N/A
6.66
6.63
908 Devices Inc. stock logo
MASS
908 Devices
N/A
3.58
3.25
Transcat, Inc. stock logo
TRNS
Transcat
0.33
2.33
1.99

Institutional Ownership

CompanyInstitutional Ownership
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
69.46%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
99.41%
908 Devices Inc. stock logo
MASS
908 Devices
88.06%
Transcat, Inc. stock logo
TRNS
Transcat
98.34%

Insider Ownership

CompanyInsider Ownership
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
10.36%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
5.13%
908 Devices Inc. stock logo
MASS
908 Devices
28.20%
Transcat, Inc. stock logo
TRNS
Transcat
2.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
500129.14 million115.76 millionOptionable
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
12083.84 million79.54 millionOptionable
908 Devices Inc. stock logo
MASS
908 Devices
6037.81 million27.15 millionOptionable
Transcat, Inc. stock logo
TRNS
Transcat
1,4139.34 million9.08 millionOptionable

Recent News About These Companies

Roubaix Capital LLC Cuts Stake in Transcat, Inc. $TRNS
Transcat Is Getting Awfully Expensive
Transcat: Mission Critical Company With A Strong Moat
Transcat (TRNS) Receives a Buy from Northland Securities

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Cytek Biosciences stock logo

Cytek Biosciences NASDAQ:CTKB

$4.49 -0.10 (-2.07%)
As of 01:18 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Eyepoint Pharmaceuticals stock logo

Eyepoint Pharmaceuticals NASDAQ:EYPT

$13.17 +0.51 (+4.04%)
As of 01:19 PM Eastern
This is a fair market value price provided by Massive. Learn more.

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

908 Devices stock logo

908 Devices NASDAQ:MASS

$7.28 +0.25 (+3.54%)
As of 01:19 PM Eastern
This is a fair market value price provided by Massive. Learn more.

908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling. Its products also comprise Maven and Trace C2, an online device for bioprocess monitoring and control; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. The company operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of the Americas. 908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Transcat stock logo

Transcat NASDAQ:TRNS

$88.16 +2.07 (+2.41%)
As of 01:18 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Transcat, Inc. provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services. This segment also provides CalTrak, a proprietary document and asset management system that is used to manage the workflow of its calibration service centers and customers' assets; and Compliance, Control and Cost, an online customer portal that provides its customers with web-based asset management capability, as well as a safe and secure off-site archive of calibration and other service records. The Distribution segment sells and rents test, measurement, and control instruments for customers' test and measurement instrumentation needs, as well as value added services, such as calibration/certification of equipment purchase, equipment rental, used equipment for sale, and equipment kitting. This segment markets and sells its products through website, digital and print advertising, proactive outbound sales, and an inbound call center. The company provides services and products to highly regulated industries, principally life science, which includes companies in the pharmaceutical, biotechnology, medical device, and other FDA-regulated industries; and additional industries, including aerospace and defense industrial manufacturing, energy and utilities, and other industries that require accuracy in processes and confirmation of the capabilities of their equipment. Transcat, Inc. was incorporated in 1964 and is headquartered in Rochester, New York.